Koutouzis, Michael <br/><br/>
Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.  [electronic resource] 

 -  Clinical cardiology  Nov 2010 
 - 686-92 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1932-8737 
<br/><br/><label>Standard No.: </label>10.1002/clc.20814  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Aged<br/>Angioplasty, Balloon, Coronary--adverse effects<br/>Antibodies, Monoclonal--administration & dosage<br/>Chi-Square Distribution<br/>Cost Savings<br/>Drug Costs<br/>Drug Substitution<br/>Eptifibatide<br/>Female<br/>Hospitals, University<br/>Humans<br/>Immunoglobulin Fab Fragments--administration & dosage<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--etiology<br/>Peptides--administration & dosage<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Proportional Hazards Models<br/>Registries<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Stroke--etiology<br/>Sweden<br/>Time Factors<br/>Treatment Outcome